{"id":835360,"date":"2025-04-09T06:53:30","date_gmt":"2025-04-09T10:53:30","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ani-pharmaceuticals-to-discuss-first-quarter-2025-financial-results-on-may-9-2025-at-800-a-m-et\/"},"modified":"2025-04-09T06:53:30","modified_gmt":"2025-04-09T10:53:30","slug":"ani-pharmaceuticals-to-discuss-first-quarter-2025-financial-results-on-may-9-2025-at-800-a-m-et","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ani-pharmaceuticals-to-discuss-first-quarter-2025-financial-results-on-may-9-2025-at-800-a-m-et\/","title":{"rendered":"ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ET"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">PRINCETON, N.J., April  09, 2025  (GLOBE NEWSWIRE) &#8212; ANI Pharmaceuticals, Inc. (\u201cANI\u201d or the \u201cCompany\u201d) (NASDAQ: ANIP) today announced that the Company will release its first quarter 2025 financial results on Friday, May 9, 2025, prior to the market open.<\/p>\n<p>Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease, will host a conference call to discuss the results as follows:<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"vertical-align: top\">Date<\/td>\n<td style=\"vertical-align: top\">Friday, May 9, 2025<\/td>\n<td style=\"vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">Time<\/td>\n<td style=\"vertical-align: top\">8:00 a.m. ET<\/td>\n<td style=\"vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">Toll free (U.S.)<\/td>\n<td style=\"vertical-align: top\">800-225-9448<\/td>\n<td style=\"vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">Conference ID<\/td>\n<td style=\"vertical-align: top\">4921902<\/td>\n<td style=\"vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">Webcast (live and replay)\u00a0<\/td>\n<td style=\"vertical-align: top\">\n            <a href=\"http:\/\/www.anipharmaceuticals.com\/\" rel=\"nofollow\" target=\"_blank\">www.anipharmaceuticals.com<\/a>, under the \u201cInvestors\u201d section<\/td>\n<td style=\"vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<\/table>\n<p>\u00a0 \u00a0 \u00a0 \u00a0\u00a0<\/p>\n<p>A replay of the conference call will be available within two hours of the call\u2019s completion and will remain accessible for two weeks by dialing 800-753-8591 and entering access code 4921902.<\/p>\n<p>\n        <strong>About ANI Pharmaceuticals, Inc. <\/strong>\n      <\/p>\n<p align=\"justify\">ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of \u201cServing Patients, Improving Lives&#8221; by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&amp;D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NLVjSQqGtmLxQohC3RFQfbqiTOiUiby9bhlG4Gqte99xDoSffTWBigb7yzhMWkWlvTSO2JCV_HT4UoQUDe53X32Dp4lPUSZxpu9Lma2W3mBzSbsg33Y6mzMre6y148x5\" rel=\"nofollow\" target=\"_blank\">www.anipharmaceuticals.com<\/a>.<\/p>\n<p>\n        <strong>Investor Relations Contact:<\/strong><br \/>\n        <br \/> Lisa M. Wilson, In-Site Communications, Inc.<br \/> 212-452-2793<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=g5SX5HtVHm0AnYaRDf0bqNnMFzd_MNbT8vodjmWYAbZG-t5aTIG9XstkBZXwSeUQn-YniZR0-bRtjkr10cg47RhmEhizQDgdQ8LWl7zt7HoekZkh_mwWpNSGUjp5X7ZcUsk8KlKoZrksflBeY0SMAgPZjM0EQtzk5kn6qJJfleXsGl1dlsQvdxWIJ2nFieJ7qrjiDKOw0v3PEUPdOWtOf7zW9Haiss-0HVL0GcJQNy6UiTGnL-uEJij3fugIPKIsB_qodkXgeoM5WY3xVs4-PQ==\" rel=\"nofollow\" target=\"_blank\">lwilson@insitecony.com<br \/><\/a><\/p>\n<p>\n        <em>SOURCE: ANI Pharmaceuticals, Inc.<\/em>\n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxOTMxMCM2ODU3ODg1IzIwMTkyNjA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NWI5OGMwNjYtMzQyZC00NjYwLWJhMzctMzI0MTgxMWVjNzZiLTEwMzA4MzMtMjAyNS0wNC0wOS1lbg==\/tiny\/ANI-Pharmaceuticals-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>PRINCETON, N.J., April 09, 2025 (GLOBE NEWSWIRE) &#8212; ANI Pharmaceuticals, Inc. (\u201cANI\u201d or the \u201cCompany\u201d) (NASDAQ: ANIP) today announced that the Company will release its first quarter 2025 financial results on Friday, May 9, 2025, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease, will host a conference call to discuss the results as follows: Date Friday, May 9, 2025 \u00a0 Time 8:00 a.m. ET \u00a0 Toll free (U.S.) 800-225-9448 \u00a0 Conference ID 4921902 \u00a0 Webcast (live and replay)\u00a0 www.anipharmaceuticals.com, under the \u201cInvestors\u201d section \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u00a0 A replay of the conference call will be available within &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ani-pharmaceuticals-to-discuss-first-quarter-2025-financial-results-on-may-9-2025-at-800-a-m-et\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ET&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-835360","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ET - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ani-pharmaceuticals-to-discuss-first-quarter-2025-financial-results-on-may-9-2025-at-800-a-m-et\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ET - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PRINCETON, N.J., April 09, 2025 (GLOBE NEWSWIRE) &#8212; ANI Pharmaceuticals, Inc. (\u201cANI\u201d or the \u201cCompany\u201d) (NASDAQ: ANIP) today announced that the Company will release its first quarter 2025 financial results on Friday, May 9, 2025, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease, will host a conference call to discuss the results as follows: Date Friday, May 9, 2025 \u00a0 Time 8:00 a.m. ET \u00a0 Toll free (U.S.) 800-225-9448 \u00a0 Conference ID 4921902 \u00a0 Webcast (live and replay)\u00a0 www.anipharmaceuticals.com, under the \u201cInvestors\u201d section \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u00a0 A replay of the conference call will be available within &hellip; Continue reading &quot;ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ET&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ani-pharmaceuticals-to-discuss-first-quarter-2025-financial-results-on-may-9-2025-at-800-a-m-et\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-09T10:53:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxOTMxMCM2ODU3ODg1IzIwMTkyNjA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ani-pharmaceuticals-to-discuss-first-quarter-2025-financial-results-on-may-9-2025-at-800-a-m-et\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ani-pharmaceuticals-to-discuss-first-quarter-2025-financial-results-on-may-9-2025-at-800-a-m-et\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ET\",\"datePublished\":\"2025-04-09T10:53:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ani-pharmaceuticals-to-discuss-first-quarter-2025-financial-results-on-may-9-2025-at-800-a-m-et\\\/\"},\"wordCount\":248,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ani-pharmaceuticals-to-discuss-first-quarter-2025-financial-results-on-may-9-2025-at-800-a-m-et\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxOTMxMCM2ODU3ODg1IzIwMTkyNjA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ani-pharmaceuticals-to-discuss-first-quarter-2025-financial-results-on-may-9-2025-at-800-a-m-et\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ani-pharmaceuticals-to-discuss-first-quarter-2025-financial-results-on-may-9-2025-at-800-a-m-et\\\/\",\"name\":\"ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ET - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ani-pharmaceuticals-to-discuss-first-quarter-2025-financial-results-on-may-9-2025-at-800-a-m-et\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ani-pharmaceuticals-to-discuss-first-quarter-2025-financial-results-on-may-9-2025-at-800-a-m-et\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxOTMxMCM2ODU3ODg1IzIwMTkyNjA=\",\"datePublished\":\"2025-04-09T10:53:30+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ani-pharmaceuticals-to-discuss-first-quarter-2025-financial-results-on-may-9-2025-at-800-a-m-et\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ani-pharmaceuticals-to-discuss-first-quarter-2025-financial-results-on-may-9-2025-at-800-a-m-et\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ani-pharmaceuticals-to-discuss-first-quarter-2025-financial-results-on-may-9-2025-at-800-a-m-et\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxOTMxMCM2ODU3ODg1IzIwMTkyNjA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxOTMxMCM2ODU3ODg1IzIwMTkyNjA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ani-pharmaceuticals-to-discuss-first-quarter-2025-financial-results-on-may-9-2025-at-800-a-m-et\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ET\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ET - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ani-pharmaceuticals-to-discuss-first-quarter-2025-financial-results-on-may-9-2025-at-800-a-m-et\/","og_locale":"en_US","og_type":"article","og_title":"ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ET - Market Newsdesk","og_description":"PRINCETON, N.J., April 09, 2025 (GLOBE NEWSWIRE) &#8212; ANI Pharmaceuticals, Inc. (\u201cANI\u201d or the \u201cCompany\u201d) (NASDAQ: ANIP) today announced that the Company will release its first quarter 2025 financial results on Friday, May 9, 2025, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease, will host a conference call to discuss the results as follows: Date Friday, May 9, 2025 \u00a0 Time 8:00 a.m. ET \u00a0 Toll free (U.S.) 800-225-9448 \u00a0 Conference ID 4921902 \u00a0 Webcast (live and replay)\u00a0 www.anipharmaceuticals.com, under the \u201cInvestors\u201d section \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u00a0 A replay of the conference call will be available within &hellip; Continue reading \"ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ET\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ani-pharmaceuticals-to-discuss-first-quarter-2025-financial-results-on-may-9-2025-at-800-a-m-et\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-09T10:53:30+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxOTMxMCM2ODU3ODg1IzIwMTkyNjA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ani-pharmaceuticals-to-discuss-first-quarter-2025-financial-results-on-may-9-2025-at-800-a-m-et\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ani-pharmaceuticals-to-discuss-first-quarter-2025-financial-results-on-may-9-2025-at-800-a-m-et\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ET","datePublished":"2025-04-09T10:53:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ani-pharmaceuticals-to-discuss-first-quarter-2025-financial-results-on-may-9-2025-at-800-a-m-et\/"},"wordCount":248,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ani-pharmaceuticals-to-discuss-first-quarter-2025-financial-results-on-may-9-2025-at-800-a-m-et\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxOTMxMCM2ODU3ODg1IzIwMTkyNjA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ani-pharmaceuticals-to-discuss-first-quarter-2025-financial-results-on-may-9-2025-at-800-a-m-et\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ani-pharmaceuticals-to-discuss-first-quarter-2025-financial-results-on-may-9-2025-at-800-a-m-et\/","name":"ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ET - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ani-pharmaceuticals-to-discuss-first-quarter-2025-financial-results-on-may-9-2025-at-800-a-m-et\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ani-pharmaceuticals-to-discuss-first-quarter-2025-financial-results-on-may-9-2025-at-800-a-m-et\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxOTMxMCM2ODU3ODg1IzIwMTkyNjA=","datePublished":"2025-04-09T10:53:30+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ani-pharmaceuticals-to-discuss-first-quarter-2025-financial-results-on-may-9-2025-at-800-a-m-et\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ani-pharmaceuticals-to-discuss-first-quarter-2025-financial-results-on-may-9-2025-at-800-a-m-et\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ani-pharmaceuticals-to-discuss-first-quarter-2025-financial-results-on-may-9-2025-at-800-a-m-et\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxOTMxMCM2ODU3ODg1IzIwMTkyNjA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxOTMxMCM2ODU3ODg1IzIwMTkyNjA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ani-pharmaceuticals-to-discuss-first-quarter-2025-financial-results-on-may-9-2025-at-800-a-m-et\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ET"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/835360","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=835360"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/835360\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=835360"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=835360"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=835360"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}